Urorec Euromedicines
Urorec Euromedicines Uses, Dosage, Side Effects, Food Interaction and all others data.
Urorec Euromedicines is a selective antagonist of post-synaptic alpha-1 adrenoreceptors, which are located in the human prostate, bladder base, bladder neck, prostatic capsule and prostatic urethra. Blockade of these alpha-1 adrenoreceptors can cause smooth muscle in these tissues to relax, resulting in an improvement in urine flow and a reduction in BPH symptoms.
Urorec Euromedicines is an antagonist of α1-adrenoceptors. It has the highest selectivity for the α1A-adrenoceptor subtype, with a 162-fold greater affinity than α1B-adrenoceptor and about a 50-fold greater affinity than for α1D-adrenoceptor. In clinical trials, silodosin improved maximum urinary flow rate, voiding symptoms, and storage symptoms of benign prostatic hyperplasia. Following oral administration, silodosin had a rapid onset of effect in men, with early effects of relieving lower urinary tract symptoms occurring within two to six hours post-dose.
Urorec Euromedicines inhibited the human ether-a-go-go-related gene (HERG) tail current; however, it has weak cardiovascular effects. As with all α1-adrenoceptor antagonists blocking α1-adrenoceptors in the iris dilator muscle, silodosin may cause intraoperative floppy iris syndrome (IFIS), which is characterized by small pupils and iris billowing during cataract surgery in patients taking α1-AR antagonists.
Trade Name | Urorec Euromedicines |
Availability | Prescription only |
Generic | Silodosin |
Silodosin Other Names | Silodosin, Silodosina |
Related Drugs | tamsulosin, finasteride, Flomax, prazosin, tadalafil, Cialis |
Type | |
Formula | C25H32F3N3O4 |
Weight | Average: 495.5345 Monoisotopic: 495.234491142 |
Protein binding | Silodosin is approximately 97% protein bound. |
Groups | Approved |
Therapeutic Class | BPH/ Urinary retention/ Urinary incontinence |
Manufacturer | |
Available Country | Spain |
Last Updated: | September 19, 2023 at 7:00 am |
Uses
Urorec Euromedicines, a selective alpha-1 adrenergic receptor antagonist, is used for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). Urorec Euromedicines is not used for the treatment of hypertension.
Urorec Euromedicines is also used to associated treatment for these conditions: Benign Prostatic Hyperplasia (BPH)
How Urorec Euromedicines works
The pathogenesis of benign prostatic hyperplasia is not fully understood: it is believed to involve several pathways, including inflammation, apoptosis, and cellular proliferation. Most drug therapies aim to alleviate symptoms of benign prostatic hyperplasia, silodosin included. Lower urinary tract symptoms of benign prostatic hyperplasia are categorized into three main groups: voiding or obstructive (hesitancy, slow stream, intermittency, incomplete emptying), storage or irritative (frequency, urgency, nocturia, urge urinary incontinence), and postmicturition (postvoid dribbling). Prostate contraction is the main contributor to lower urinary tract symptoms of benign prostatic hyperplasia. The smooth muscle tone of the prostate is regulated by α1A-adrenoceptors, which are the most highly expressed subtype of α1adrenoceptors in the human prostate tissue. It has been reported that blockade of α1A-adrenoceptors relieves bladder outlet obstruction. Blockade of α1D-adrenoceptors, another subtype found in prostate tissue, is believed to alleviate storage symptoms due to detrusor overactivity.
α1-adrenoceptors are G protein-coupled receptors: upon binding of its natural ligand, norepinephrine and epinephrine, leads to the activation of phospholipase C and downstream signalling molecules, including inositol triphosphate and diacylglycerol. Ultimately, there is an increase in intracellular calcium levels and, consequently, smooth muscle contraction. Urorec Euromedicines is an antagonist of α1-adrenoceptors, with the highest selectivity for the α1A-adrenoceptor subtype. By blocking the α1A-adrenoceptor signalling pathway, silodosin promotes prostatic and urethral smooth muscle relaxation, thereby improving lower urinary tract symptoms such as voiding. Urorec Euromedicines also targets afferent nerves in the bladder, relieving bladder overactivity and storage symptoms.
Dosage
Urorec Euromedicines dosage
The recommended dose is Urorec Euromedicines 8 mg orally once daily with a meal.4 mg capsules taken orally once daily with a meal for those with moderate renal impairment (CrCl 30-50 mL/min).
Side Effects
Most common adverse reactions are retrograde ejaculation, dizziness, diarrhea, orthostatic hypotension, headache, nasopharyngitis and nasal congestion.
Toxicity
Oral LD50 is 800 mg/kg in rats.
In clinical trials, postural hypotension was the most common dose-limiting adverse event. In case of drug overdose leading to hypotension, the patient should be placed in a supine position to restore blood pressure and normalize heart rate. Further measures, such as administration of intravenous fluids, may be initiated. In case of the use of vasopressors, renal function should be monitored and supported as needed. Since silodosin is highly bound to plasma proteins, dialysis is unlikely to be beneficial.
Precaution
Postural hypotension with or without symptoms (e.g. dizziness) may develop when beginning Urorec Euromedicines treatment. Urorec Euromedicines should not be used in combination with other alpha-blocker. Inform patients planning cataract surgery to notify their ophthalmologist that they are taking Urorec Euromedicines because of the possibility of Intraoperative Floppy Iris Syndrome (IFIS)
Interaction
Strong P-glycoprotein inhibitors (e.g., cyclosporine): Co-administration may increase plasma Urorec Euromedicines concentration. Concomitant use of PDE5 inhibitors with alpha-blockers including Urorec Euromedicines can potentially cause symptomatic hypotension.
Food Interaction
- Take with food. A moderate fat or calorie meal decreases drug exposure as well as the risk of adverse effects.
[Moderate] ADJUST DOSING INTERVAL: Food may reduce the oral bioavailability of silodosin.
The effect of a moderate-fat, moderate-calorie meal on silodosin pharmacokinetics was variable and decreased silodosin maximum plasma concentration (Cmax) by approximately 18% to 43% and systemic exposure (AUC) by 4% to 49% across three different studies.
The maximum effect of food (i.e., coadministration with a high-fat, high-calorie meal) on the pharmacokinetics of silodosin was not evaluated.
Safety and efficacy clinical trials for silodosin were always conducted in the presence of food intake.
MANAGEMENT: Patients should be instructed to take silodosin with a meal to reduce the risk of adverse events.
Urorec Euromedicines Alcohol interaction
[Moderate] GENERALLY AVOID:
The concurrent use of ethanol and alpha-1 adrenergic blockers may cause increased hypotensive effects.
Patients with aldehyde dehydrogenase deficiencies (primarily Asians) may be at a higher risk of this interaction.
The mechanism has not been determined.
Data exist for prazosin and other alpha adrenergic blockers are expected to interact also.
In addition, any patients taking alpha adrenergic blockers may experience excessive orthostatic hypotension with ethanol ingestion, due to ethanol's unopposed vasodilatory effects in the presence of alpha adrenergic blockade.
Patients who develop
a flushing reaction after ethanol ingestion (indicates a possible aldehyde dehydrogenase deficiency) should be advised to avoid ethanol or limit their intake.
All patients should be warned about the possibility of orthostatic hypotension with concurrent ethanol use.
Urorec Euromedicines Drug Interaction
Moderate: tadalafil, metoprolol, metoprololUnknown: aspirin, aspirin, ubiquinone, rosuvastatin, duloxetine, apixaban, omega-3 polyunsaturated fatty acids, atorvastatin, pregabalin, polyethylene glycol 3350, mirabegron, acetaminophen, acetaminophen, cyanocobalamin, ascorbic acid, cholecalciferol, rivaroxaban
Urorec Euromedicines Disease Interaction
Major: hepatic impairment, severe renal impairmentModerate: hypotension, cataracts
Volume of Distribution
Urorec Euromedicines has an apparent volume of distribution of 49.5 L.
Elimination Route
The absolute bioavailability is approximately 32%. Following oral administration of silodosin 8 mg once daily in healthy male subjects, Cmax was 61.6 ± 27.54 ng/mL and AUC was 373.4 ± 164.94 ng x hr/mL. The Tmax was 2.6 ± 0.90 hours. Urorec Euromedicines glucuronide or KMD-3213G, the main metabolite of silodosin, has an AUC three- or four fold higher than for the parent compound.
A moderate fat or calorie meal reduces Cmax by 18% to 43% and AUC by 4% to 49%, as well as Tmax by about one hour. However, the US prescribing information recommends drug intake with meals to avoid the potential adverse effects associated with high plasma drug concentrations.
Half Life
The elimination half-life of silodosin is 13.3 ± 8.07 hours. KMD-3213G, the main metabolite of silodosin, has an extended half-life of approximately 24 hours.
Clearance
After intravenous administration, the plasma clearance of silodosin was approximately 10 L/hour.
Elimination Route
At 10 days following oral administration of radiolabelled silodosin, about 33.5% of the dose was recovered in urine and 54.9% was recovered in feces.
Pregnancy & Breastfeeding use
Pregnancy Category B. Urorec Euromedicines is not indicated for use in women. An embryo/fetal study in rabbits showed decreased maternal body weight at 200 mg/kg/day (approximately 13-25 times the maximum recommended human exposure or MRHE of Urorec Euromedicines via AUC). No statistically significant teratogenicity was observed at this dose. Urorec Euromedicines was not teratogenic when administered to pregnant rats during organogenesis at 1000 mg/kg/day (estimated to be approximately 20 times the MRHE). No maternal or fetal effects were observed at this dose. Rats and rabbits do not produce glucuronidated Urorec Euromedicines, which is present in human serum at approximately 4 times the level of circulating Urorec Euromedicines and which has similar pharmacological activity to Urorec Euromedicines. No effects on physical or behavioral development of offspring were observed when rats were treated during pregnancy and lactation at up to 300 mg/kg/day.
Contraindication
Patients with severe renal & hepatic impairment, concomitant administration with strong Cytochrome P450 3A4 (CYP3A4) inhibitors (e.g., ketoconazole, clarithromycin, itraconazole, ritonavir) and patients with a history of hypersensitivity to Urorec Euromedicines.
Special Warning
Pediatric patients: Urorec Euromedicines is not indicated for use in pediatric patients.
Geriatric use: In double-blind, placebo-controlled, 12-week clinical studies of Urorec Euromedicines, 259 (55.6%) were under 65 years of age, 207 (44.4%) patients were 65 years of age and over, while 60 (12.9%) patients were 75 years of age and over. Orthostatic hypotension was reported in 2.3% of Urorec Euromedicines patients < 65 years of age (1.2% for placebo), 2.9% of Urorec Euromedicines patients > 65 years of age (1.9% for placebo), and 5.0% of patients > 75 years of age (0% for placebo). There were otherwise no significant differences in safety or effectiveness between older and younger patients.
Renal impairment: Urorec Euromedicines is contra-indicated in patients with severe renal impairment (CCr <30 mL/min). In patients with moderate renal impairment (CCr 30-50 mL/min), the dose should be reduced to Urorec Euromedicines 4 mg once daily taken with a meal. No dosage adjustment is needed in patients with mild renal impairment (CCr 50-80 mL/min).
Hepatic impairment: Urorec Euromedicines has not been studied in patients with severe hepatic impairment (Child-Pugh score > 10) and is therefore contra-indicated in these patients. No dosage adjustment is needed in patients with mild or moderate hepatic impairment.
Acute Overdose
Urorec Euromedicines was evaluated at doses of up to 48 mg/day in healthy male subjects. The dose-limiting adverse event was postural hypotension. Should overdose of Urorec Euromedicines lead to hypotension, support of the cardiovascular system is of first importance. Restoration of blood pressure and normalization of heart rate may be accomplished by maintaining the patient in the supine position. If this measure is inadequate, administration of intravenous fluid should be considered. If necessary, vasopressors could be used, and renal function should be monitored and supported as needed. Dialysis is unlikely to be of significant benefit since Urorec Euromedicines is highly (97%) protein bound.
Storage Condition
Store in a cool and dry place, protected from light.
Innovators Monograph
You find simplified version here Urorec Euromedicines
Urorec Euromedicines contains Silodosin see full prescribing information from innovator Urorec Euromedicines Monograph, Urorec Euromedicines MSDS, Urorec Euromedicines FDA label
FAQ
What is Urorec Euromedicines used for?
Urorec Euromedicines is an alpha-blocker that is used to improve urination in men with benign prostatic hyperplasia (enlarged prostate).
Urorec Euromedicines may also be used for purposes not listed in this medication guide.
How should I take Urorec Euromedicines?
Follow all directions on your prescription label and read all medication guides or instruction sheets. Your doctor may occasionally change your dose. Use the medicine exactly as directed.Take once daily with a meal.If you cannot swallow a capsule whole, open it and mix the medicine with applesauce. Swallow the mixture right away without chewing.
How safe is Urorec Euromedicines?
Urorec Euromedicines is an effective and safe agent in elderly men who are taking antihypertensive medications. Urorec Euromedicines has an advantage in the treatment of LUTS in this population, even if the patients have orthostatic hypotension before treatment.
What are the common side effects of Urorec Euromedicines?
The most common side effects are include:
- dizziness
- diarrhea
- orthostatic hypotension (low blood pressure when you stand up after sitting or lying down)
- headache
- retrograde ejaculation (occurs when semen enters the bladder instead of out the tip of the penis)
- common cold
- stuffy nose
Is Urorec Euromedicines safe during pregnancy?
Women should not take Urorec Euromedicines, especially if they are or could become pregnant .
Is Urorec Euromedicines safe during breastfeeding?
This drug is not indicated for use in female patients.
Can I drink alcohol with Urorec Euromedicines?
avoid or limit alcohol-containing beverages while taking Urorec Euromedicines.
Can I drive after taking Urorec Euromedicines?
Urorec Euromedicines may cause some people to become dizzy or less alert than they are normally. Do not drive or do anything else that could be dangerous until you know how this medicine affects you.
When is the best time to take Urorec Euromedicines?
This drug should be taken with a meal.Taking this drug on an empty stomach may increase your risk of side effects, such as a drop in blood pressure when rising after sitting or lying down.Take this drug at the same time every day.
How long does Urorec Euromedicines stay in my system?
The terminal half-life of Urorec Euromedicines is about 11 hours.
How quickly does Urorec Euromedicines work?
Most people in studies saw improvements in their prostate symptoms within the first month of the study.
Does Urorec Euromedicines make me tired?
You should know that Urorec Euromedicines may make you drowsy or dizzy, especially when you first start taking it. Do not drive a car or operate machinery until you know how this medication affects you.
Can I take Urorec Euromedicines at night?
Your first dose of Urorec Euromedicines with food at bedtime so that your body can get used to its effects. The dosage is based on your medical condition and response to treatment. Take this medication regularly to get the most benefit from it.
Does Urorec Euromedicines cause retrograde?
The ejaculatory dysfunction caused by Urorec Euromedicines was a loss of seminal emission, not retrograde ejaculation.
What happens if I miss a dose of Urorec Euromedicines?
Take the medicine as soon as you can, but skip the missed dose if it is almost time for your next dose. Do not take two doses at one time.
Does Urorec Euromedicines help in erection?
Most patients using Urorec Euromedicines per day for BPH treatment experienced improvement in their erectile function, estimated IELT, and premature ejaculation profile in the third month of the treatment.
Can Urorec Euromedicines cause incontinence?
Urorec Euromedicines can cause problems in urinating, such as a need to urinate often, a weak stream when urinating, or a feeling of not being able to empty the bladder completely.
How long can I take Urorec Euromedicines?
It may take up to 4 weeks to notice an improvement in symptoms but keep taking them regularly. Tell your doctor if your symptoms do not improve after 4 weeks or if they get worse
What happens if I take too much Urorec Euromedicines?
If you take too much, you may experience low blood pressure, especially when you stand up after sitting or lying down. Symptoms may include: feeling dizzy or lightheaded. fainting.